Forceps for Pancreatitis

Phase-Based Progress Estimates
Pancreatitis+1 More
Forceps - Device
All Sexes
What conditions do you have?

Study Summary

This trial is investigating whether or not using a forceps to assist in cannulation during ERCP decreases the incidence of PEP.

Eligible Conditions
  • Pancreatitis
  • Post ERCP Acute Pancreatitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 5 (+/- 2) days after ERCP

5 (+/- 2) days after ERCP
Number of Post-ERCP Pancreatitis (PEP)
Baseline (during the ERCP)
Number of Difficult Cannulation

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

No Forceps Assisted Cannulation
1 of 2
Forceps Assisted Cannulation
1 of 2

Active Control

Experimental Treatment

152 Total Participants · 2 Treatment Groups

Primary Treatment: Forceps · No Placebo Group · N/A

Forceps Assisted Cannulation
Experimental Group · 1 Intervention: Forceps · Intervention Types: Device
No Forceps Assisted CannulationNoIntervention Group · 1 Intervention: No Forceps Assisted Cannulation · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 (+/- 2) days after ercp

Who is running the clinical trial?

Dartmouth-Hitchcock Medical CenterLead Sponsor
482 Previous Clinical Trials
2,533,484 Total Patients Enrolled
7 Trials studying Pancreatitis
1,045 Patients Enrolled for Pancreatitis
Timothy B Gardner, MD MSPrincipal InvestigatorDartmouth-Hitchcock Medical Center

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have difficulty cannulating the PD catheter.
You have type 2, 3, or 4 papillae.
You have a native papilla.
A papilla is present in a diverticulum.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 15th, 2021

Last Reviewed: November 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.